12111 Parklawn Drive
13 articles with ViGene Biosciences
Further Expands Charles River’s Scientific Capabilities in the High-Growth Cell and Gene Therapy CDMO Sector
Fueled by billions of dollars invested by the federal government to battle the ongoing COVID-19 pandemic, companies across the BioCapital region have expanded their footprint and number of employees.
Vigene Strengthens Management Team with Another Key Executive Addition as Business Expansion Continues
Vigene Biosciences, an award-winning world leader in plasmid and viral vector development and manufacturing, announces today another key executive addition. Audrey Chang, Ph.D. is appointed as the VP of QC and Analytical Services.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 31, 2020.
Vigene Biosciences Awarded Patent for improvements in the packaging efficiency of recombinantly-modified adeno-associated virus (AAV)
ROCKVILLE, Md. , Feb. 24, 2020 /PRNewswire/ -- Vigene Biosciences, Inc. (Vigene), a leading biotechnology company for viral vector production and development for cell and gene therapies, announced the award of a patent from USPTO on recombinantly-modified adeno-associated virus (AAV) helper vectors that are capable of increasing the packaging efficiency of recombinantly-modifi
ASC Therapeutics and Vigene Announce Long-Term Strategic Partnership for Gene Therapy Development and Manufacturing
ASC Therapeutics, a privately-held gene therapy company focused on developing transformative gene-based medicines for serious diseases, announced that it has entered into a long-term strategic manufacturing partnership with Vigene Biosciences, a Maryland-based Contract Develop and Manufacturing Organization.
The investment was made by Signet Healthcare Partners ("Signet"), a New York based growth equity firm specializing in healthcare investments.
Inc. magazine collates an annual list of the fastest-growing private companies in America. This year, 15 of the top 5,000 were related to healthcare, medical devices and biopharma.
Inc. magazine today revealed that ViGene Biosciencesis No. 81 on its 37th annual Inc. 5000, the most prestigious ranking of the nation's fastest-growing private companies.
Vigene Biosciences, Inc. has been recognized as the 2018 Emerging Growth Company of the Year by ACG National Capital.
Vigene Biosciences Partners With The Michael J. Fox Foundation to Distribute Alpha-synuclein Knockdown Viral Vectors for Parkinson's Disease Research
Viral vectors to knockdown mouse or human alpha-synuclein (aSyn) will be made available for purchase in early 2018.
ViGene Biosciences Introduces World's Largest Collection of Pre-Made Human Full-Length cDNA ORF and miRNA Adenoviruses